Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) – Equities researchers at Zacks Investment Research lifted their FY2017 EPS estimates for shares of Can-Fite BioPharma in a research note issued on Wednesday. Zacks Investment Research analyst G. Zeng now forecasts that the biotechnology company will earn ($0.59) per share for the year, up from their prior forecast of ($0.62).
Other equities research analysts also recently issued research reports about the stock. Maxim Group restated a “buy” rating and issued a $7.00 price objective on shares of Can-Fite BioPharma in a research note on Friday, September 1st. HC Wainwright set a $6.00 price objective on shares of Can-Fite BioPharma and gave the stock a “buy” rating in a research note on Thursday, August 10th. Finally, ValuEngine downgraded shares of Can-Fite BioPharma from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 7th.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.com-unik.info/2017/12/05/fy2017-eps-estimates-for-can-fite-biopharma-ltd-lifted-by-analyst-canf.html.
About Can-Fite BioPharma
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
What are top analysts saying about Can-Fite BioPharma Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Can-Fite BioPharma Ltd. and related companies.